ES2191065T3 - Linfocitos t dirigidos. - Google Patents

Linfocitos t dirigidos.

Info

Publication number
ES2191065T3
ES2191065T3 ES95937931T ES95937931T ES2191065T3 ES 2191065 T3 ES2191065 T3 ES 2191065T3 ES 95937931 T ES95937931 T ES 95937931T ES 95937931 T ES95937931 T ES 95937931T ES 2191065 T3 ES2191065 T3 ES 2191065T3
Authority
ES
Spain
Prior art keywords
lymphocytes
directed
diana
cells
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937931T
Other languages
English (en)
Inventor
Bradley Michael John Stringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFactors PLC
Original Assignee
CellFactors PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellFactors PLC filed Critical CellFactors PLC
Application granted granted Critical
Publication of ES2191065T3 publication Critical patent/ES2191065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LINFOCITOS T CITOTOXICOS DIRIGIDOS TIENEN UN TCR QUE COMPRENDE POLIPEPTIDOS {AL} Y {BE} HETEROLOGOS, LOS CUALES CONFIEREN AL LINFOCITO MHC DE CLASE I RESTRINGIDO ESPECIFICIDAD PARA CELULAS DIANA QUE CAUSAN ENFERMEDADES. LOS LINFOCITOS PUEDEN SER MONOVALENTES, CON UNA ESPECIE UNICA DE TCR QUE CONFIERE ESPECIFICIDAD A UNA UNICA CLASE DE CELULAS DIANA. LOS LINFOCITOS ENCUENTRAN APLICACION COMO VACUNAS Y EN INMUNOTERAPIA ADOPTIVA, P. EJ., CANCER, SIDA O TERAPIA ANTIVIRAL.
ES95937931T 1994-11-16 1995-11-16 Linfocitos t dirigidos. Expired - Lifetime ES2191065T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423085A GB9423085D0 (en) 1994-11-16 1994-11-16 Targeted T lymphocytes

Publications (1)

Publication Number Publication Date
ES2191065T3 true ES2191065T3 (es) 2003-09-01

Family

ID=10764464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937931T Expired - Lifetime ES2191065T3 (es) 1994-11-16 1995-11-16 Linfocitos t dirigidos.

Country Status (16)

Country Link
EP (1) EP0792354B1 (es)
JP (1) JPH10511542A (es)
KR (1) KR970707280A (es)
AT (1) ATE231550T1 (es)
AU (1) AU687271B2 (es)
CA (1) CA2203934A1 (es)
CZ (1) CZ289455B6 (es)
DE (1) DE69529473T2 (es)
DK (1) DK0792354T3 (es)
ES (1) ES2191065T3 (es)
GB (1) GB9423085D0 (es)
HU (1) HUT77472A (es)
MX (1) MX9703535A (es)
NZ (1) NZ295418A (es)
PT (1) PT792354E (es)
WO (1) WO1996015238A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1012259E (pt) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
WO2003068819A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
IT202100019334A1 (it) * 2021-07-21 2023-01-21 Univ Degli Studi Di Pavia Metodo per l’identificazione dell’intera sequenza della regione variabile delle catene pesanti e leggere di immunoglobuline
US20240398902A1 (en) * 2021-09-13 2024-12-05 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
JP3072330B2 (ja) * 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
EP0568623A1 (en) * 1991-01-22 1993-11-10 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
AU3875495A (en) 1996-06-06
NZ295418A (en) 2000-02-28
DE69529473T2 (de) 2004-01-08
MX9703535A (es) 1997-08-30
CA2203934A1 (en) 1996-05-23
GB9423085D0 (en) 1995-01-04
CZ289455B6 (cs) 2002-01-16
PT792354E (pt) 2003-06-30
EP0792354B1 (en) 2003-01-22
WO1996015238A1 (en) 1996-05-23
DK0792354T3 (da) 2003-05-19
HUT77472A (hu) 1998-05-28
EP0792354A1 (en) 1997-09-03
DE69529473D1 (de) 2003-02-27
ATE231550T1 (de) 2003-02-15
KR970707280A (ko) 1997-12-01
JPH10511542A (ja) 1998-11-10
AU687271B2 (en) 1998-02-19
CZ144297A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
MX9203439A (es) Una citocina mamifera, il-11
CR20230303A (es) Composiciones y métodos para reducir el mhc de clase ii en una célula
PT879282E (pt) Imunoterapia utilizando linfocitos t citotoxicos (ctl)
DK421383D0 (da) Humant interleukin
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
MX9703535A (es) Linfocitos t dirigidos.
SE8501709L (sv) Forbettringar inom eller som henfor sig till interleukinterapi
DE3684220D1 (de) Zusammensetzung mit verzoegerter abgabe.
ES2197500T3 (es) Uso de cloruro de n,n-bis(fenilcarbamoilmetil)dimetilamonio y sus usos derivados en el tratamiento del dolor cronico.
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
MX9603431A (es) Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.
IL139950A0 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
DE59407809D1 (de) Tumorizide t-lymphozyten
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ES2061787T3 (es) Combinacion de inhibidores de la enzima de conversion de la angiotensina con moduladores del canal del potasio, asi como su empleo en medicamentos.
ATE71149T1 (de) Monoklonale antikoerper.
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
ES8701772A1 (es) Procedimiento para preparar complejos organicos de platino
DK4586D0 (da) Fremgangsmaade til formering af begoniearter
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DE3675631D1 (de) In-vitro-kulturverfahren.
MY150767A (en) Polyethylene glycol modifications of thymosin alpha 1
ES2051788T3 (es) Un producto farmaceutico.